Catalyst pharmaceuticals

Dedicated to Making a Meaningful Difference in the Lives of Patients Suffering from Rare and Difficult to Treat Diseases

NASDAQ: CPRX

March 2024

BIOFLORIDA 2022 Company of the Year

Safe Harbor

This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All statements regarding our strategy, future operations, financial position, estimated revenues or losses, projected costs, prospects, plans, and objectives, other than statements of historical fact included in our filings with the U.S. Securities and Exchange Commission ("SEC"), are forward-looking statements. The language reflected in these statements only speaks as of the date that appears on the front cover of the presentation; the words "may," "will," "could," "would," "expect," "intend," "plan," "anticipate," "believe," "estimate," "project," "potential," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should not place undue reliance on forward-looking statements. While we believe that we have a reasonable basis for each forward-looking statement that we make, we caution you that these statements are based on a combination of facts and factors currently known by us and projections of future events or conditions about which we cannot be certain. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect our business, particularly those mentioned in the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC, reporting our financial position and results of operations as of and for the year ended December 31, 2023, as well as our subsequent reports filed with the SEC. In addition, market and industry statistics contained in this presentation are based on information available to us that we believe is accurate. This information is generally based on publications that are not produced for purposes of securities offerings or economic analysis. All forward-looking statements speak only as of the date that appears on the front cover of the presentation or the date of this presentation. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Catalyst Pharmaceuticals

A Differentiated Growth Rare Disease Company

Commercial Excellence

Proven track record commercializing innovative, rare, and best-in-class neurological medicines

Strategic Portfolio Expansion

Demonstrated success acquiring and integrating high-value, complimentary neurological assets to drive strong and sustained growth

Highly Qualified Leadership Team

Decades of combined industry experience, with extensive expertise spanning neurology, rare disease, and new product launches

Strong Financial Position

Positive cash flow and strong revenue growth enable continued execution against strategic priorities including neurological portfolio expansion to further drive growth

Growing Revenues with a Diversified Portfolio

Focus on Rare Neurological and Epileptic Disorders

Proprietary Portfolio

Neuromuscular

FIRDAPSE® - rare neuromuscular disease

AGAMREE® - rare muscular dystrophy disease

Epilepsy

FYCOMPA® - epileptic seizures

Product Franchises

Neuromuscular	Epilepsy
FIRDAPSE® (amifampridine) Tablets 10 mg aGamree® (vamorolone) oral suspension 40mg/mL	Fycompa™ (perampanel) tablets CII 2mg • 4mg • 6mg • 8mg • 10mg • 12mg

Proven U.S. Commercial Capabilities

Neuromuscular Franchise

FIRDAPSE: Proprietary Flagship Product

Only U.S. Approved Treatment for Lambert Eaton Myasthenic Syndrome (LEMS)

FIRDAPSE® (amifampridine) Tablets 10mg

Orally Delivered Potassium Channel Blocker

Clinically Proven to Maintain Muscle Strength and Mobility
Most Patients Respond and Remain on Treatment

Flagship product; approved in the U.S. in November 2018

Product launched - Q1 2019

Approved in people ≥6 years of age

Orphan Drug Exclusivity through 2025

Strong intellectual property estate enhances durability

IP protection to 2037

Total of 9 patents: 6 Listed in the Orange Book

Catalyst pharmaceuticals

Lambert Eaton Myasthenic Syndrome (LEMS)

A Rare Neuromuscular Autoimmune Disease

Affects Nerve-Muscle Communication



Most affected

Sometimes affected

Least affected

May cause:

- Weakening of upper arms and shoulders muscles
- Severe, debilitating, and progressive weakness in the upper legs and hips
- Life-threatening weakness in respiratory muscles

Causes Debilitating, Progressive Muscle Weakness and Fatigue

50% of people with LEMS have underlying cancer

Observed in ~3% of small cell lung cancer patients

Affects both women and men

*O'Neill, J H, Murry, N M, Newson-Davis, J: (1988): The Lambert-Eaton myasthenic syndrome. A review of 50 cases: doi: 10.1093/brain/111.3.577

FIRDAPSE: U.S. LEMS Market Opportunity

Significant Unmet Need

Affects at Least 3,600 and Potentially up to 5,400 LEMS Patients (U.S.)[1]

>1,100 LEMS diagnosed patients ever **treated** with FIRDAPSE [2]

~500 LEMS patients **diagnosed but not yet treated** with FIRDAPSE

> **2,900 LEMS undiagnosed** patients

Multiple Growth Drivers

Expanded educational programs to SCLC LEMS HCP's

Seeking to expand FIRDAPSE maximum daily dose from 80mg to 100mg

sNDA for the 100 mg daily dose assigned a U.S. PDUFA action date of June 4, 2024

Making A Meaningful Difference In Patients' Lives

[1] *Lambert Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data*; presented IASLC 2023 World Conference on Lung Cancer; authors: David Morrell, Benjamin Drapkin, Guy Shechter, Regina Grebla;[2] Includes 225 patients now deceased

FIRDAPSE: Small Cell Lung Cancer Tumor LEMS

Represents a Significant Growth Opportunity

Patient prevalence Lung Cancer

Small Cell Lung Cancer (SCLC)
(10% - 15% of Lung Cancer – midpoint 12.5%)

Lambert Eaton Myasthenic Syndrome SCLC patients
(~3% of SCLC)



- Many SCLC LEMS patients are undiagnosed with LEMS and are being treated by oncologists
- Oncologists typically refer SCLC patients diagnosed with LEMS to neurologists or neuromuscular specialists
- **~ 1,000 new potential** SCLC LEMS patients each year (*includes diagnosed and undiagnosed*)

Catalyst pharmaceuticals

FIRDAPSE: Expanding the Global Reach

Global Expansion Initiatives Underway

Japan

Currently, no approved therapy for LEMS

LEMS prevalence: ~1,200 people

DyDo Pharma* to develop & market the product

DyDo NDA accepted by the PMDA in Dec 2023*

Anticipate a 9-month priority review cycle time

If approved, the Japan launch expected in 1H 2025

Expect 10-year market exclusivity upon approval

Canada

Approved by Health Canada on July 31, 2020

Canada LEMS Prevalence: ~300 people

KYE Pharmaceuticals has the exclusive license to market FIRDAPSE

Innovative drug data exclusivity to 2028

No drug application referencing data accepted before 2026

*Under the amendment to our FIRDAPSE® license agreement that added Japan to our territory, upon the acceptance of DyDo's NDA by the PMDA (Japanese regulatory agency), which occurred on December 18, 2023, our territory in which we have the right to seek to commercialize FIRDAPSE® has automatically expanded to include several countries in Asia and Latin America; Source Catalyst Pharmaceuticals 2023 10K

AGAMREE: Novel Corticosteroid

Treatment for Duchenne Muscular Dystrophy (DMD)

aGamree® (vamorolone) oral suspension 40mg/mL

Designations:
Orphan Drug
Rare Pediatric Disease

Potential to Deliver Meaningful Near & Long-term Value, Adding to Continued Growth Momentum

Approved in the U.S. for treatment in DMD patients ≥ 2yrs - October 2023

May increase ambulation duration and mobility, improving QoL

Product launch expected in Q1 2024

Optimize neuromuscular franchise capabilities with minimal expansion

Comprehensive Patient Assistance Program available upon launch

Orphan drug designation offers 7 years of market exclusivity

Patents out to 2040; 6 patents listed in the Orange Book

Acquired North America License from Santhera Pharmaceuticals, July 2023. North American territories consist of the U.S., Canada, and Mexico
†Santhera Pharmaceuticals to commercialize in European Union. Germany launch expected 1Q 2024.

AGAMREE: Addresses Need for Tolerable Steroid

Steroids are the Backbone of DMD Therapy

AGAMREE - Compelling Safety Profile

In Clinical Studies, Demonstrated[1]

Proven efficacy, tolerability, safety, and ease of use

Equivalent efficacy to prednisone

Potential of significant reduction of steroid associated side effect burden when compared with another corticosteroid, with benefits for:

- Bone Health
- Growth
- Behavior

U.S. DMD patient prevalence: ~ 11,000 to 13,000

DMD diagnosis rate; typically occurs at ages 2 - 5 years

DMD patients treated with corticosteroids at some point

Currently treated DMD patients receive concomitant steroid treatment



[1]Guglieri M et al (2022). JAMA Neurol. 2022;79(10):1005-1014.doi:10.1001/jamaneurol.2022.2480; Mah JK et al (2022). JAMA NetwOpen.2022; e2144178.doi:10.1001/jamanetworkopen.2021.44178.; Guglieri M et al (2022) JAMA. doi:10.1001/jama.2022.4315;Heier CR et al (2019); Life Science Alliance DOI: 10.26508; Liu X et al (2020). Proc Natl Acad Sci USA 117:24285-24293

Catalyst pharmaceuticals

Epilepsy Franchise

FYCOMPA® (perampanel) CIII

Established, First-in-Class Commercial Epilepsy Asset

Synergistic Neurology Expansion

Acquired U.S. rights in January 2023

Franchise teams fully engaged - May 2023

Franchise physician call points overlap - 45%

Compelling product net revenue contribution

Seek to expand into rare epilepsy or other neuroscience adjacencies

FYCOMPA® is approved to treat:

SEIZURES WITH CONVULSIONS		SEIZURES WITHOUT CONVULSIONS
Partial-onset seizures that **secondarily generalize***	**Primary generalized** tonic-clonic seizures†	**Partial-onset** seizures that do not secondarily generalize*

*Taken with another antiseizure medication or alone for patients 4 years of age and older.

†Taken with another antiseizure medication for patients 12 years of age and older.

Catalyst pharmaceuticals

FYCOMPA: Broad Spectrum Efficacy

Only Non-Competitive AMPA Receptor Antagonist

Well-tolerated, minimal drug-to-drug interactions, and no contraindications

Simple once-a-day dosing

Long half-life, relieving the anxiety of breakthrough seizures if a dose is missed

>70% retention rate for adult patients

Seizure-freedom rate is ˜ 72% when used adjunctively

Patent exclusivity until at least May 2025

FYCOMPA has been designated in the U.S. as a federally-controlled substance (CIII). For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit www.fycompa.com.

Catalyst pharmaceuticals

FYCOMPA: Attractive Market Opportunity

Epilepsy - High Unmet Medical Need

Epilepsy is 4th most common neurological disorder after migraine, stroke and Alzheimer's disease[1]

- ~3.4M patients in the U.S. with active epilepsy and ~470K children[2]
- ~150,000 new patients per year in U.S.[3]
- ~30 - 40% of all people with epilepsy still fail to respond to treatment despite the availability of a wide variety of anti-seizure medications

Treatment for epilepsy is evolving into a precision medicine composed of a variety of well-defined rare epilepsies of genetic origin

Fycompa™

[1]England MJ, Liverman CT, Schultz AM, Strawbridge LM, eds. Epilepsy Across the Spectrum: Promoting Health and Understanding. Washington, DC: National Academies Press (US); 2012. [2]CDC Epilepsy Data and Statistics; Epilepsy Prevalence in the US (data as of 2015); [3]Examining the Economic Impact and Implications of Epilepsy, AJMC (US); 2020

Catalyst pharmaceuticals

Catalyst Portfolio

Catalyst Pharmaceuticals Portfolio



[1]EAP=Expanded Access Program; ISI investigator Sponsored IND

[2]Orphan Drug Designation

[3]Breakthrough Therapy Designation

[4]Lead Indication

*FIRDAPSE is currently approved in the U.S. for the treatment of LEMS in patients 6 years of age and older

Corporate Highlights

Sustained QoQ Product Portfolio Growth

Demonstrated Commercial Execution

Q4 22 vs Q4 23 Net Revenue Performance

FIRDAPSE
Q4 22 vs. Q4 23

FYCOMPA
Q4 22 vs. Q4 23



TOTAL NET REVENUES
Q4 22 vs. Q4 23



Catalyst pharmaceuticals

FY 2023 Financial Highlights

Achieved Record FY 2023 Total Product Revenues

(Dollars in thousands, except share data)

For the Year Ended December 31st	2023	2022	% Change
Total Net Product Revenues	$396,502	$213,938	85.3%
FIRDAPSE Net Product Revenues	$258,426	$213,938	20.8%
FYCOMPA Net Product Revenues	$138,076	N/A	N/A
GAAP Net Income (Loss)	$71,410	$83,079	(14.0%)
Non-GAAP Net Income *	$223,155	$113,865	96.0%
GAAP Net Income (Loss) Per Share – Diluted	$ 0.63	$ 0.75	(16.0%)
Non-GAAP Net Income Per Share – Diluted*	$ 1.96	$ 1.02	92.2%

* Non-GAAP net income excludes from the calculation of net income (i) the expense associated with non-cash stock-based compensation, (ii) non-cash depreciation expense, (iii) non-cash amortization of intangible assets expense, (iv) the provision (benefit) for income taxes and (v) acquired in-process research & development costs. Non-GAAP financial measures are provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance.

Strong Financial Position

Underscores Successful Execution

(Dollars In Millions)

Q4 23 Results	
Cash Position as of Dec 31, 2023*	$137.6
Total Product Net Revenue for the three months ended Dec 31, 2023	$109.1
Total Revenue Growth compared to Q4 2022	82.0%
Net Product Revenue Growth Increase	
FIRDAPSE 2023 FY, as of Dec 31, 2023	20.8%
FYCOMPA compared to Q3 2023	8.0%



* On January 9, 2024, added $140.1 million, net resulting from equity raise.

Catalyst pharmaceuticals

Continued Drivers to Deliver Long-Term Value

	2023 Accomplishments	Anticipated 2024 Milestones
Catalyst pharmaceuticals	Launched inaugural ESG report Expanded product portfolio with 2 additional products	Continue to pursue synergistic rare CNS opportunities
FIRDAPSE® (amifampridine) Tablets 10 mg	Expanded focus to SCLC patients comorbid with LEMS	Pursuing global expansion of FIRDAPSE as a treatment for LEMS
	sNDA for 100mg maximum daily dose accepted	**June 4, 2024:** assigned U.S. PDUFA date
	NDA submission in Japan complete	Submitted by partner DyDo Pharma Expect a 9-month PMDA review period in Japan
	Received two new patent issued	Further strengthens intellectual property estate that has patent protection until 2037
aGamree® (vamorolone) oral suspension 40mg/mL	Received FDA approval	**Q1 2024:** Expect U.S. commercial launch
Fycompa™ (perampanel) tablets CII 2mg • 4mg • 6mg • 8mg • 10mg • 12mg	Completed U.S. commercial and MSL team integration	

Strategic Growth Initiatives

Building on the Momentum

Expand Commercial Footprint	Explore commercial add-on assets both in the US and globally Synergistic expertise to foster innovations Harness operational capabilities and industry expertise
Expand Portfolio in Rare & Orphan Diseases	Seek partnerships to accelerate growth into new therapeutic areas and larger markets focused on rare (orphan) neurological and adjacent rare (orphan) disease opportunities Geographical expansion of our portfolio products
Invest in Portfolio Diversification	Strong balance sheet reinforces delivering attractive opportunities Well-positioned to achieve long-term growth

NASDAQ: CPRX